basal cell carcinoma
EMA adds warning label to Novartis’ MS treatment Gilenya
December 22, 2015Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya
Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
FDA approves Novartis drug Odomzo
July 27, 2015Sales and Marketing Novartis, Odomzo, basal cell carcinoma, skin cancer
The FDA has given the Swiss firm the go-ahead to market its drug for skin cancer. Odomzo (sonidegib, formerly LDE225) …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
